Johns Hopkins ABX Guide
Imipenem/relebactam
INDICATIONS
FDA
FDA
- Infections caused by susceptible Gram-negative bacteria for patients who have limited or no alternative treatment options, who are ≥ 18 y/o; approval of these indications is based on limited clinical safety and efficacy data.
- Treatment of complicated urinary tract infections, including pyelonephritis (cUTI)
- Complicated intra-abdominal infections (cIAI)
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- MDR infections including bacteremia, pneumonia, osteomyelitis
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: February 10, 2020
Citation
Avdic, Edina. "Imipenem/relebactam." Johns Hopkins ABX Guide, The Johns Hopkins University, 2020. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540727/7/Imipenem_relebactam.
Avdic E. Imipenem/relebactam. Johns Hopkins ABX Guide. The Johns Hopkins University; 2020. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540727/7/Imipenem_relebactam. Accessed January 13, 2025.
Avdic, E. (2020). Imipenem/relebactam. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540727/7/Imipenem_relebactam
Avdic E. Imipenem/relebactam [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2020. [cited 2025 January 13]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540727/7/Imipenem_relebactam.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Imipenem/relebactam
ID - 540727
A1 - Avdic,Edina,Pharm.D.
Y1 - 2020/02/10/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540727/7/Imipenem_relebactam
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
